A0152000
Acetylcysteine impurity C
European Pharmacopoeia (EP) Reference Standard
Synonym(s):
N,N′-Diacetyl-L-cystine, NSC 203780
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
grade
pharmaceutical primary standard
API family
acetylcysteine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
InChI
1S/C10H16N2O6S2/c1-5(13)11-7(9(15)16)3-19-20-4-8(10(17)18)12-6(2)14/h7-8H,3-4H2,1-2H3,(H,11,13)(H,12,14)(H,15,16)(H,17,18)
InChI key
YTPQSLLEROSACP-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Application
This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia. Their suitability for any other use is not guaranteed and is the sole responsibility of the user. This standard is not intended for human or animal use.
Established for the preparation of reference solution (c) in testing for related substances in acetylcysteine using liquid chromatography (General text 2.2.29), according to the monograph 0967 of European Pharmacopeia.
Established for the preparation of reference solution (c) in testing for related substances in acetylcysteine using liquid chromatography (General text 2.2.29), according to the monograph 0967 of European Pharmacopeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
M Wågberg et al.
The Journal of pharmacology and experimental therapeutics, 299(1), 76-82 (2001-09-19)
Oxidation of lipoprotein-derived lipids is generally accepted to be important in atherogenesis, and lipophilic antioxidants have been suggested as potential antiatherosclerotic agents. The antiatherogenic effects observed by certain antioxidants, especially probucol, in different animal models support this suggestion. There are
Knut Pettersson et al.
Atherosclerosis, 196(1), 275-282 (2006-12-13)
To investigate if the immunomodulator drug DINAC (1) affects arterial dimensions in asymptomatic patients with hypercholesterolemia, (2) has effects on leucocyte markers of inflammation and (3) has in vitro effects on nitric oxide synthase (NOS) in human umbilical vein endothelial
B Särnstrand et al.
The Journal of pharmacology and experimental therapeutics, 288(3), 1174-1184 (1999-02-23)
Oral N-acetyl-L-cysteine (NAC) is used clinically for treatment of chronic obstructive pulmonary disease. NAC is easily oxidized to its disulfide. We show here that N,N'-diacetyl-L-cystine (DiNAC) is a potent modulator of contact sensitivity (CS)/delayed type hypersensitivity (DTH) reactions in rodents.
Pei Wang et al.
Yao xue xue bao = Acta pharmaceutica Sinica, 39(10), 782-786 (2005-02-11)
To study the therapeutic effects of N,N'-diacetyl-L-cystine (DiNAC) on immunological liver failure. Serum ALT, AST and T cell subsets in peripheral blood of the experimental animals during the trial period were analyzed by an automatic serum analyzer and a flow
Sheila A Doggrell
Expert opinion on investigational drugs, 11(5), 717-720 (2002-05-09)
Not all antioxidants reduce atherosclerosis. This may be because atherosclerosis has an autoimmune, inflammatory pathogenesis. As probucol is both an antioxidant and an immunomodulatory drug, it may be the immunomodulatory effect that underlies its ability to reduce atherosclerosis. N,N-Diacetyl-L-cystine is
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service